ATIC

Across TCGA pan-cancer cohorts, ATIC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATIC data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATIC mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATIC expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where ATIC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.629	0.460	.009	15	view →
HNSC	OS	Quartile	IV	0.709	0.908	.024	10	view →
LUAD	DFS	Median	All	0.436	0.747	.010	4	view →
LSCC	OS	Tertile	All	0.785	0.922	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATIC–PDAC (OS)

Open the PDAC breakdown →